<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825266</url>
  </required_header>
  <id_info>
    <org_study_id>SU-09052008-1295</org_study_id>
    <secondary_id>IRB#7432</secondary_id>
    <nct_id>NCT00825266</nct_id>
  </id_info>
  <brief_title>Insulin Resistance in Pulmonary Arterial Hypertension</brief_title>
  <official_title>The Effect of Bosentan and Pioglitazone on Insulin Resistance in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate 1) the incidence of insulin resistance (a
      pre-diabetic state) in patients with pulmonary hypertension, and 2) test the utility of a
      validated PH therapy (Tracleer) versus Pioglitazone in the treatment of those patients found
      to have insulin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Effect of Bosentan and Pioglitazone on Insulin Resistance in Pulmonary Arterial
      Hypertension ,is a study evaluating the incidence of insulin resistance in patients with
      pulmonary hypertension and testing the utility of a validated PH therapy(Tracleer) versus
      Pioglitazone in the treatment of those patients found to have insulin resistance.Patients
      with PAH must be stable on therapy for at least 3 months are considered for enrollment in
      this study.With the exception of PAH, subjects must be free of major medical illnesses,
      including diabetes mellitus ,malignancy or significant hepatic or renal disease.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty in finding eligible subjects
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Resistance Profile Change - Triglyceride:HDL Cholesterol Ratio</measure>
    <time_frame>baseline and 16 weeks</time_frame>
    <description>insulin resistance measured -triglyceride: HDL cholesterol ratio measures at 16 weeks compared with baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>6 minute walk test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes.It assess the disease severity of the subject at 16 week compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA (New York Heart Association Classification) Changes</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>New York Heart Classification(NYHA) changes measured at 16 weeks compared with baseline.
NYHA Classification:
NYHA class I:no symptoms and no limitation in ordinary physical activity NYHA class II:Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity NYHA class III:Marked limitation in activity due to symptoms, even during less-than-ordinary activity, NYHA class IV:Severe limitations. Experiences symptoms even while at rest. {Higher NYHA class represent worse symptoms}</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>bosentan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.</description>
    <arm_group_label>bosentan</arm_group_label>
    <other_name>Tracleer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with Pulmonary Arterial Hypertension (PAH) must be stable on therapy for at least
        3 months prior to enrollment in the trial. We will include patients with idiopathic PAH and
        Familial PAH as well as PAH associated with collagen vascular disease or drug or toxin
        exposure. With the exception of PAH, subjects must be free of major medical illnesses,
        including diabetes mellitus (must have fasting plasma glucose &lt; 126 mg/dL and taking no
        anti-hyperglycemic agent), malignancy or significant hepatic or renal disease. Subjects may
        be hypertensive and on anti-hypertensive medications as long as blood pressure is &lt; 150/100
        mm Hg. Subjects may also be dyslipidemic and/or taking drugs to improve abnormalities of
        lipid metabolism, but they will be excluded if they are taking medications known to alter
        insulin sensitivity, including glucocorticoids, niacin, anti-retrovirals,
        thiazolidinediones, or metformin. Use of oral contraceptives or estrogen and/or
        progesterone replacement therapy is permitted. Weight must be stable and the subjects agree
        not to change their eating habits or exercise regimen during the study period. There will
        be no restrictions with regard to race or socioeconomic status, and the racial/ethnic
        composition of the study population will be reflective of the communities surrounding the
        Stanford University Medical Center.

        Exclusion Criteria:

        * Vulnerable subject status.

          -  Concurrent Endothelin-1 antagonist therapy

          -  Concurrent Thiazolidinedione therapy

          -  New York Heart Class III or IV

          -  PAH related to other etiologies.

          -  Diabetes Mellitus with Fasting Glucose Levels &gt; 126 mg/dL

          -  Allergy or hypersensitivity to pioglitazone or bosentan administration.

          -  Current treatment with statin therapy.

          -  Initiation of PAH therapy (prostacyclin analogues, phosphodiesterase-5 inhibitors)
             within three months of enrollment.

          -  Inability or unwillingness to avoid systemic steroid containing medications for four
             months. Inhaled steroid use is acceptable.

          -  Current or recent use or planned treatment with: glyburide, cyclosporine, nilotinib,
             nisoldipine, ranolazine, thioridazine

          -  Hepatic transaminases &gt; 2x the upper limit of normal at the center at screening.

          -  Current or recent (&lt; 6 months) chronic heavy alcohol consumption.

          -  Current use of another investigational drug (non-FDA approved) for PAH.

          -  Lung transplant recipients.

          -  History of myositis.

          -  Renal failure (Cr 2.0).

          -  Hospitalized or acutely ill.

          -  Chronic liver disease (cirrhosis, chronic hepatitis, etc.).

          -  Abnormalities of the arm or hand or radical mastectomy (preventing brachial artery
             ultrasound).

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roham T. Zamanian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <results_first_submitted>November 21, 2016</results_first_submitted>
  <results_first_submitted_qc>February 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2017</results_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Roham T. Zamanian</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>pulmonary hypertension &amp; insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bosentan</title>
          <description>Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
bosentan: Bosentan 62.5 mg twice daily for 4 weeks, then 125mg BID for duration of study.</description>
        </group>
        <group group_id="P2">
          <title>Pioglitazone</title>
          <description>Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
Pioglitigone: Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bosentan</title>
          <description>Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
bosentan: Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.</description>
        </group>
        <group group_id="B2">
          <title>Pioglitazone</title>
          <description>Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
Pioglitigone: Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="61" upper_limit="61"/>
                    <measurement group_id="B2" value="51" lower_limit="51" upper_limit="51"/>
                    <measurement group_id="B3" value="56" lower_limit="51" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Resistance Profile Change - Triglyceride:HDL Cholesterol Ratio</title>
        <description>insulin resistance measured -triglyceride: HDL cholesterol ratio measures at 16 weeks compared with baseline.</description>
        <time_frame>baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bosentan</title>
            <description>Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
bosentan: Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
Pioglitigone: Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance Profile Change - Triglyceride:HDL Cholesterol Ratio</title>
          <description>insulin resistance measured -triglyceride: HDL cholesterol ratio measures at 16 weeks compared with baseline.</description>
          <units>ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22"/>
                    <measurement group_id="O2" value="-1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6 Minute Walk Test</title>
        <description>6 minute walk test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes.It assess the disease severity of the subject at 16 week compared to the baseline.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bosentan</title>
            <description>Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
bosentan: Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
Pioglitigone: Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Walk Test</title>
          <description>6 minute walk test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes.It assess the disease severity of the subject at 16 week compared to the baseline.</description>
          <units>meters</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71"/>
                    <measurement group_id="O2" value="-23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NYHA (New York Heart Association Classification) Changes</title>
        <description>New York Heart Classification(NYHA) changes measured at 16 weeks compared with baseline.
NYHA Classification:
NYHA class I:no symptoms and no limitation in ordinary physical activity NYHA class II:Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity NYHA class III:Marked limitation in activity due to symptoms, even during less-than-ordinary activity, NYHA class IV:Severe limitations. Experiences symptoms even while at rest. {Higher NYHA class represent worse symptoms}</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bosentan</title>
            <description>Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
bosentan: Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
Pioglitigone: Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.</description>
          </group>
        </group_list>
        <measure>
          <title>NYHA (New York Heart Association Classification) Changes</title>
          <description>New York Heart Classification(NYHA) changes measured at 16 weeks compared with baseline.
NYHA Classification:
NYHA class I:no symptoms and no limitation in ordinary physical activity NYHA class II:Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity NYHA class III:Marked limitation in activity due to symptoms, even during less-than-ordinary activity, NYHA class IV:Severe limitations. Experiences symptoms even while at rest. {Higher NYHA class represent worse symptoms}</description>
          <units>NYHA class</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bosentan</title>
          <description>Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
bosentan: Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.</description>
        </group>
        <group group_id="E2">
          <title>Pioglitazone</title>
          <description>Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
Pioglitigone: Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated due to poor enrollment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Roham Zamanian</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-725-5495</phone>
      <email>roham.zamanian@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

